The classic post-transplant infection framework — bacterial, viral, fungal & PJP risk mapped across the surgical, peak-immunosuppression, and maintenance periods
In the first month after solid organ transplantation, immunosuppression has typically not yet reached its steady maximal net effect, and the classic opportunistic pathogens have not yet had time to reactivate or establish infection. Instead, risk is dominated by the same factors that drive infection after any major surgery: technical complications, indwelling devices, hospitalization, and whatever organisms travelled with the graft itself.
The recipient has just undergone major surgery: an incision, an anastomosis, drains, and typically a urinary catheter and central or peripheral vascular access. Each of these breaches a natural barrier and creates an opportunity for bacterial (and occasionally fungal) colonization to become invasive infection.
Common early problems include surgical-site infection at the wound or perinephric/perihepatic space, catheter-associated urinary tract infection, central-line-associated bloodstream infection, ventilator-associated pneumonia in patients requiring prolonged intubation, and anastomotic leaks that seed the peritoneal or thoracic cavity.
Organisms are typically the same hospital-acquired pathogens seen after any major operation — gram-negative rods, enterococci, staphylococci — sometimes multidrug-resistant given prior hospitalization and antibiotic exposure. Standard perioperative antibacterial prophylaxis targets this window; opportunistic-infection prophylaxis is not yet the priority.
Two risk sources are specific to transplantation itself rather than to surgery in general.
Donor-derived infection: pathogens present in the donor at the time of procurement — bacteria, fungi, or latent viruses — can be transmitted with the organ. Donor cultures and serologies are screened, but occult or unrecognized donor infection remains a rare but important early cause of infection, and unexplained early sepsis in a transplant recipient should prompt review of donor history.
Technical and anatomic complications: vascular thrombosis, ureteral or biliary leaks/strictures, hematoma, and lymphocele create fluid collections that are prone to secondary bacterial or fungal seeding. These technical problems, more than immunosuppression, are usually the proximate cause when infection occurs in this earliest window — which is why the first-month framework is often described as "surgery-driven" rather than "immunosuppression-driven."
A useful clinical rule of thumb: infection in the first month after transplant should first prompt a search for a surgical, technical, or nosocomial explanation — not an opportunistic-pathogen work-up — because net immunosuppression has not yet reached the level required for classic opportunists to emerge.
Between roughly one and six months post-transplant, cumulative and maintenance immunosuppression reach their greatest net effect on host defense. This is the period in which the "classic" opportunistic infections of transplantation — cytomegalovirus (CMV) and other herpesviruses, Pneumocystis jirovecii pneumonia (PJP), invasive fungal disease, and reactivation of latent pathogens such as tuberculosis — are most likely to appear, often overlapping in time within the same patient.
"Net state of immunosuppression" is the sum of induction therapy, maintenance immunosuppressive drugs, any treatment for rejection, and host factors such as neutropenia, uremia, or malnutrition. In the first weeks, induction agents and higher maintenance doses are typically still active, and the cumulative immunologic effect on T-cell and innate defenses is at its highest.
This is precisely the environment in which latent viruses reactivate (CMV, EBV, BK polyomavirus, VZV/HSV), slow-growing fungi establish invasive disease (Aspergillus, endemic fungi), and PJP — an organism essentially universally present at low levels in the environment/host — becomes pathogenic. Multiple of these processes commonly overlap in the same patient during the same months, which is why this window is framed as a convergence rather than a single-pathogen problem.
Cytomegalovirus is the single most studied opportunistic pathogen in this window and is often used as the sentinel example of the broader pattern: seronegative recipients of seropositive grafts (D+/R−) face the highest primary-infection risk, while seropositive recipients face reactivation risk under high immunosuppression. CMV disease can directly cause fever, colitis, pneumonitis, and marrow suppression, and is also linked indirectly to graft rejection and to increased susceptibility to other infections.
This timeline simulator treats CMV as one representative viral band among several rather than the primary subject — a companion page in this series (CMV Reactivation & Transplant Monitoring Simulator) is dedicated specifically to CMV serostatus risk-stratification, viral-load monitoring, and preemptive-versus-prophylactic treatment strategy in depth.
Invasive fungal disease — most commonly invasive candidiasis (often earlier, overlapping the surgical period) and invasive aspergillosis (often peaking within this 1–6 month window, especially in lung and some liver/heart recipients) — shares the same risk driver: peak net immunosuppression combined, in some cases, with prior antibacterial exposure, indwelling devices, and, for lung transplant specifically, direct airway exposure to environmental mold. Endemic fungi (Histoplasma, Coccidioides) can also reactivate from latent infection in this period in relevant geographic regions.
PJP (Pneumocystis jirovecii pneumonia) is grouped with these because, like CMV and invasive fungal disease, it is essentially never seen in the first days post-transplant but becomes a significant threat once net immunosuppression is sustained — which is exactly why routine PJP prophylaxis is started early and continued through this window regardless of an individual patient's measured immune status.
The defining feature of the 1–6 month period is not any single pathogen but the temporal overlap of several opportunistic-infection risks driven by one shared cause — peak net immunosuppression — which is why prophylactic regimens for multiple pathogen classes are deliberately concentrated in this same window rather than staggered.
Because the opportunistic-infection risks of months one through six are predictable in timing and pathogen identity, transplant protocols respond with standardized prophylactic regimens rather than waiting for infection to occur. Three prophylaxis "bars" are typically overlaid directly on top of the peak-risk timeline: PJP prophylaxis, CMV antiviral prophylaxis or preemptive monitoring, and antifungal coverage where risk warrants it.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line agent for PJP prophylaxis across essentially all solid organ transplant types, valued for also covering several bacterial pathogens and Toxoplasma reactivation. It is typically started early post-operatively and continued for a minimum duration (commonly around 6–12 months, and often lifelong in lung transplantation) that is set by protocol rather than by individually measuring PJP risk day-to-day — because PJP risk tracks the same net-immunosuppression curve for essentially every recipient.
When TMP-SMX cannot be used (sulfa allergy, cytopenia), alternatives such as dapsone, atovaquone, or inhaled/IV pentamidine are substituted, generally with somewhat lower efficacy and no antibacterial/antitoxoplasma coverage.
CMV management follows one of two overlapping strategies during this window: universal prophylaxis (valganciclovir given to all at-risk patients for a defined duration, most aggressively in D+/R− recipients) or preemptive therapy (regular viral-load PCR monitoring with antiviral treatment triggered only once replication is detected). Both approaches are deliberately concentrated across the same 1–6+ month period where opportunistic risk peaks.
Antifungal coverage is more selectively overlaid: high-risk populations (lung transplant recipients, those with early technical complications, prior colonization, or high-dose steroid treatment for rejection) receive targeted mold-active or Candida-active prophylaxis, while lower-risk recipients may receive none beyond routine perioperative coverage. Layering all three prophylaxis bars together over the peak-risk window is the operational expression of the three-period timeline framework — treat the calendar, not just the symptom.
Overlaying prophylaxis on a predictable risk window is what allows transplant teams to convert several distinct, individually dangerous opportunistic infections into rare events — the prophylaxis bars are timed to the immunosuppression curve, not to symptoms, because by the time symptoms appear the infection is often already established.
Beyond roughly six months, most recipients have been weaned to lower maintenance immunosuppression and prophylactic regimens are tapered or discontinued per protocol. The infection profile shifts: instead of the classic transplant opportunists, community-acquired respiratory infections, urinary tract infections, and reactivation of chronic viral disease become relatively more prominent — though the recipient's baseline risk never returns fully to that of a non-immunosuppressed person.
With induction agents long cleared and maintenance immunosuppression reduced to lower chronic dosing, most recipients in stable condition beyond six months face an infection risk profile that increasingly resembles — but does not equal — that of the general population. Seasonal respiratory viruses (influenza, RSV, and others), community-acquired pneumonia, urinary tract infections (especially in kidney recipients), and gastrointestinal infections become the more frequent reasons for presentation, simply because the classic opportunists have receded as net immunosuppression falls.
Routine vaccination (where live vaccines remain contraindicated but inactivated vaccines are encouraged), general infection-prevention counseling, and prompt evaluation of fevers remain part of long-term care, but the intensity of pathogen-specific prophylaxis is reduced accordingly.
Some risks specifically persist or only emerge in the late period: chronic CMV or EBV-related disease (including post-transplant lymphoproliferative disorder, most associated with EBV, in the setting of long-term immunosuppression), late fungal infections in patients with ongoing risk factors, and reactivation of latent infections such as tuberculosis or endemic mycoses that can present even years after transplantation.
Because a transplant recipient never returns to fully unmodified immune function, "late period" does not mean "low risk" in an absolute sense — it means relatively lower risk than the peak window, with a different, more community-flavored pathogen mix layered on top of a permanently elevated baseline.
The late period is best understood as a floor, not a return to zero: prophylaxis intensity is tapered because opportunistic risk has fallen, but the recipient remains more susceptible than an immunocompetent person for the rest of their life, and any new immunosuppression intensification (see Stage 5) can reopen the earlier risk windows.
The three-period framework describes a typical, uncomplicated course — but it is a starting template, not a fixed calendar. A rejection episode requiring augmented immunosuppression, an unusual environmental or donor exposure, or a complicated post-operative course can shift a patient back into "peak-risk" physiology regardless of how many months have elapsed since transplant, and prophylaxis duration must be individualized accordingly.
Treating acute rejection typically means adding high-dose corticosteroids, antithymocyte globulin (ATG), or other lymphocyte-depleting or intensified maintenance therapy on top of whatever regimen the patient was already on. This acutely raises the net state of immunosuppression, effectively re-creating the physiologic conditions of the original 1–6 month peak-risk period — even if the patient is, by calendar time, a year or more post-transplant.
Accordingly, transplant protocols typically restart or extend PJP prophylaxis, CMV monitoring or prophylaxis, and antifungal vigilance for a defined period following rejection treatment, rather than treating the patient as though they remain in the "late period" simply because enough calendar months have passed since the original operation.
Other scenarios that shift the standard timeline include: unusual exposures (a construction-related mold exposure prompting antifungal vigilance regardless of month post-transplant), high-risk serostatus combinations that warrant longer CMV prophylaxis than a standard protocol duration, recurrent or breakthrough infection prompting secondary prophylaxis, and multi-organ or re-transplant recipients who may carry elevated baseline risk for longer.
The practical takeaway of the whole timeline framework is therefore two-layered: use the standard early/peak/late template as the default scaffold for prophylaxis planning, but treat any event that meaningfully raises net immunosuppression — most commonly a rejection episode — as a trigger to re-evaluate and individually extend prophylaxis duration rather than following the original calendar.
A rejection episode does not just treat the graft — it resets the infection-risk clock. The correct response is not to ask "how many months post-transplant is this patient?" but "what is this patient's current net state of immunosuppression?" — and to extend prophylaxis for as long as that elevated state persists.